

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-5 (cancelled).

Claim 6 (Currently amended). A method of producing a bioactive peptide, wherein said peptide is 7 to 25 amino acids in length, has at least 3 cationic amino acids and is capable of forming an amphipathic α -helix, which method comprises representing the peptide as a 2-dimensional α -helical wheel, identifying ~~identification of~~ a cationic sector and dividing ~~division of~~ the remaining part of the peptide into three further sectors which are substantially equal in size, incorporating ~~incorporation~~ into the sector which is opposite the cationic sector within the α -helical wheel representation of the peptide ~~of~~ no more than 1 bulky and lipophilic amino acids, incorporating ~~incorporation~~ into the two sectors flanking the cationic sector ~~of~~ 2 or more bulky and lipophilic amino acids, and synthesizing ~~synthesis of~~ said peptide.

Claim 7 (cancelled).

Claim 8 (Previously presented) A method as claimed in claim 6 wherein one or more of the bulky and lipophilic amino acids is tryptophan or an analogue thereof.

Claim 9 (Previously presented). A method as claimed in claim 6 or 8 wherein all of the bulky and lipophilic amino acids are tryptophan or analogues thereof.

Claim 10 (Cancelled).

Claim 11 (Previously presented). A method as claimed in claim 6, 8 or 9 wherein the peptide is 12 to 25 amino acids in length.

Claim 12 (Cancelled).

Claim 13 (Previously presented). A method as claimed in claim 6, 8, 9 or 24 wherein the peptide comprises at least 7 cationic residues.

Claims 14-19 (Cancelled).

Claim 20 (Previously presented) A method for the production of a pharmaceutical composition comprising a method of peptide production as claimed in claim 6 and mixing of the compound prepared thereby or a derivative thereof with a pharmaceutically acceptable carrier.

Claims 21-23 (Cancelled).

Claim 24 (Previously presented). A method as claimed in claim 6, 8 or 9 wherein the peptide comprises at least 5 cationic residues.